A cancer theory kerfuffle can lead to new lines of research

Journal of the National Cancer Institute

Volumn 107, Issue 2, 2015, Pages

  Baker, Stuart G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; DNA; ENZYME INHIBITOR;

CANCER DIAGNOSIS; CANCER RESEARCH; CARCINOGENESIS; DENERVATION; EARLY DIAGNOSIS; ENZYME INHIBITION; FAMILIAL CANCER; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; SOMATIC MUTATION THEORY; TISSUE ORGANIZATION FIELD THEORY; TUMOR REGRESSION; ANIMAL; CANCER TRANSPLANTATION; CELL TRANSFORMATION; COMPLICATION; DNA SEQUENCE; FOREIGN BODY; GENETIC PROCEDURES; GENETICS; INDUCTION CHEMOTHERAPY; MUTATION; NEOPLASM; PATHOLOGY; RESEARCH; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOGENESIS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DENERVATION; DNA, NEOPLASM; ENZYME INHIBITORS; FOREIGN BODIES; GENETIC TECHNIQUES; HUMANS; INDUCTION CHEMOTHERAPY; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; RESEARCH; SEQUENCE ANALYSIS, DNA;

EID: 84925546905     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju405     Document Type: Review

References (131)

1. Reece JB, Urry LA, Cain ML, Wasserman SA, Minorsky PV, Jackson RB. Campbell Biology. 9th Edition. San Francisco, CA: Pearson Benjamin Cummings; 2011:379.
2. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27-40.
3. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
4. Rous P. Surmise and fact on the nature of cancer. Nature. 1959;183(4672):1357-1361.
5. Rosenbaum PR. Choice as an alternative to control in observational studies. Statist Sci. 1999;14(3):259-304.
6. Feyerabend P. Against Method. London, UK: Verso; 1975.
7. Moore R. Niels Bohr: The Man, His Science, and the World They Changed. New York, NY: Alfred Knopf; 1966.
8. Chamberlin C. The method of multiple working hypotheses. Science. 1965;148(3671):754-759.
9. Sonnenschein C, Soto AM. The Society of Cells: Cancer and Control of Cell Proliferation. New York, NY: Springer-Verlag; 1999.
10. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays. 2004;26(10):1097-1107.
11. Potter JD. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer. 2007;7(6):464-474.
12. Schwartz L, Balosso J, Baillet F, Brun B, Amman JP, Sasco AJ. Cancer: the role of extracellular disease. Med Hypotheses. 2002;58(4):340-346.
13. Soto AM, Sonnenschein CS. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays. 2011;33(5):332-340.
14. Marongiu F, Doratiotto S, Sini M, Serra MP, Laconi E. Cancer as a disease of tissue pattern formation. Prog Histochem Cytochem. 2012;47(3):175-207.
15. Levin M. Morphogenetic fields in embryogenesis, regeneration, and cancer: non-local control of complex patterning. Biosystems. 2012;109(3):243-261.
16. Baker SG. Paradoxes in carcinogenesis should spur new avenues of research: An historical perspective. Disrupt Sci Technol. 2012;1(2):100-107.
17. Baker SG. Paradox-driven cancer research. Disrupt Sci Technol. 2013;1(3):143-148.
18. Sonnenschein C, Soto AM, Rangarajan A, Kulkarni P. Competing views on cancer. J Biosci. 2014;39(2):281-302.
19. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? BioMed Res Int. 2014;2014:934038.
20. Baker SG. Recognizing paradigm instability in theories of carcinogenesis. Br J Med Med Res. 2014;4(5):1149-1163.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
22. Weinberg RA. In Retrospect: The chromosome trail. Nature. 2008;453(7196):725.
23. Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer. 1954;8(1):1-12.
24. Platt R. Clonal ageing and cancer. Lancet. 1955;265(6869):867.
25. Armitage P, Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer. 1957;11(2):161-169.
26. Nowell PC, Hungerford DA. Minute chromosome in human chronic granulocytic leukemia. Science. 1960;132(3538):1497.
27. Huebner RJ, Todaro GJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci U S A. 1969;64(3):1087-1094.
28. Stehelin D, Varmus HE, Bishop JM, et al. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976;260:170-173.
29. Stratton MR, Campbell PJ, Futreal A. The cancer genome Nature. 2009;458(7239):719-724.
30. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982;300(5888):149-152.
31. Tabin CJ, Bradley SM, Bargmann CI, et al. Mechanism of activation of a human oncogene. Nature. 1982;300(5888):143-149.
32. Osborne C1, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9(4):361-377.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
34. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153-158.
35. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869-873.
36. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
37. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
38. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-1120.
39. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med. 2014;6(1):5.
40. Zhang J, Liu J, Sun J, Chen C, Foltz G, Lin B. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. Brief Bioinform. 2014;15(2):244-255.
41. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451-2459.
42. Liu H, Radisky DC, Yang D, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of (alpha)v and (beta)3 integrin subunits. Nat Cell Biol. 2012;14(6):567-574.
43. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell. 2014;157(1):267-271
44. Prehn RT. Cancers beget mutations versus mutations beget cancer. Cancer Res. 1994;54(20):5296-5300.
45. Orr JW. The mechanism of chemical carcinogenesis. Br Med Bull. 1958;14(2):99-101.
46. Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Semin Reprod Med. 1999;17(3):275-290.
47. Tarin D. Tissue interactions in morphogenesis, morphostasis and carcinogenesis J Theor Biol. 1972;34(1):61-72.
48. Potter JD. Morphostats: a missing concept in cancer biology. Cancer Epidemiol Biomarkers Prev. 2001;10(3):161-170.
49. Van den Brink GR, Hardwick JC, Tytgat GN, et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology. 2001;121(2):317-328.
50. Van den Brink GR, Offerhaus GJ. The morphogenetic code and colon cancer development. Cancer Cell. 2007; 11(2):109-117.
51. Faucheux C, Nesbitt SA, Horton MA, Price JS. Cells in regenerating deer antler cartilage provide a microenvironment that supports osteoclast differentiation. J Exp Biol. 2001;204(3):443-455.
52. Borgens RB. Mice regrow the tips of their foretoes. Science. 1982;217(4561):747-750.
53. Seifert AW, Kiama SG, Seifert MG. Skin shedding and tissue regeneration in African spiny mice (Acomys). Nature. 2012;489(7417):561-565.
54. Booth BW, Mack DL, Androutsellis-Theotokis A, McKay RD, Boulanger CA, Smith GH. The mammary microenvironment alters the differentiation repertoire of neural stem cells. Proc Natl Acad Sci U S A. 2008;105(39):14891-14896.
55. Miyoshi H, Ajima R, Luo CT. WNT5a potentiates TGF signaling to promote colonic crypt regeneration after tissue injury. Science. 2012;338(6103):108-113.
56. Takeo M, Chou WC, Sun Q, et al. WNT activation in nail epithelium couples nail growth to digit regeneration. Nature. 2013;499(7457):228-232.
57. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical WNT signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 2003;17(14):1709-1713.
58. Molchadsky A, Rivlin N, Brosh R, Rotter V. Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis. 2010;31(9):1501-1508.
59. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol. 1995;5(8):931-936.
60. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol. 2005;64(4):458-475.
61. Bienz M, Clevers H. Linking colorectal cancer to WNT signalling. Cell. 2000;103(2):311-320.
62. Dale TC, Weber-Hall SJ, Smith K, et al. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res. 1996;56(19):4320-4323.
63. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848-851.
64. Donnelly JM, Chawla A, Houghton J, and Zavros Y. Sonic hedgehog mediates the proliferation and recruitment of transformed mesenchymal stem cells to the stomach. PLoS One. 2013;8:e75225.
65. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425(6960):846-851.
66. Lawrence PA. The making of a fly. Oxford, UK: Blackwell Scientific Publications; 1992:206.
67. Driever W, Nüsslein-Volhard C. The bicoid protein determines position in the Drosophila embryo in a concentrationdependent manner. Cell. 1988;54(1):95-104.
68. Shyer AE, Tallinen T, Nerurkar NL, et al. Villification: how the gut gets its villi. Science. 2013;342(6155):212-218.
69. Tanner K., Mori H, Mroue R, Bruni-Cardoso A, Bissell MJ. Coherent angular motion in the establishment of multicellular architecture of glandular tissues. Proc Natl Acad Sci U S A. 2012;109(6):1973-1978.
70. Lucitti JL, Jones EA, Huang C, Chen J, Fraser SE, Dickinson ME. Vascular remodeling of the mouse yolk sac requires hemodynamic force. Development. 2007;134(18):3317-3326.
71. Patwari P. Lee RT. Mechanical control of tissue morphogenesis. Circ Res. 2008;103(3):234-243.
72. Heller E, Kumar KV, Grill SW, Fuchs E. Forces generated by cell intercalation tow epidermal sheets in mammalian tissue morphogenesis. Dev Cell. 2014;28(6):617-632.
73. Barnes C, Speroni L, Quinn KP, et al. From single cells to tissues: interactions between the matrix and human breast cells in real time. PLoS ONE. 2014;9(4):393325.
74. Jaalouk DE Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol. 2009;10(1):63-73.
75. Yang M, Brackenbury WJ. Membrane potential and cancer progression. Front Physiol. 2013;4:185.
76. Chernet B, Levin M. Endogenous voltage potentials and the microenvironment: bioelectric signals that reveal, induce and normalize cancer. J Clin Exp Oncol. 2013;S1:1-29.
77. Blackiston D, Adams DS, Lemire JM, Lobikin M, Levin M. Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. Dis Model Mech. 2011;4(1):67-85.
78. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344-358.
79. M Sternlicht, A Lochter, C Sympson, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999;98(2):137-146.
80. Lorimore SA, Coates PJ, Wright EG. Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation. Oncogene. 2003;22(45):7058-7069.
81. Nomura S, Kaminishi M, Sugiyama K, Oohara T, Esumi H. Clonal analysis of isolated intestinal metaplastic glands of stomach using X linked polymorphism. Gut. 1998;42(5):663-668.
82. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-399.
83. Cairns J. The origin of human cancers. Nature. 1981;289(5796):353-357.
84. Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol. 2006;37(5-7):225-238.
85. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-857.
86. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431(7012):1112-1117.
87. Horne SD, Stevens JB, Abdallah BY, et al. Why imatinib remains an exception of cancer research. J Cell Physiol. 2013;228(4):665-670.
88. Coulombe L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med. 1983;308(25):1493-1498.
89. Weisberg E, Griffin JD. CML cell trafficking: Influence of the stromal microenvironment. Open J Hematol. 2012;3(S1):-2.
90. Zhang B, Li M, McDonald T, et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and WNT-catenin signaling. Blood. 2013;121(10):1824-1838.
91. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
92. Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657-667.
93. Turner FC. Sarcomas at sites of subcutaneously implanted bakelite disks in rats. J Natl Cancer Inst. 1941;2(1):81-83.
94. Bischoff F, Bryson G. Carcinogenesis through solid state surfaces. Prog Exp Tumor Res. 1964;5:85-133.
95. Karp RD, Johnson KH, Buoen LC, Ghobrial HK, Brand I, Brand KG. Tumorigenesis by Millipore filters in mice: histology and ultrastructure of tissue reactions as related to pore size. J Natl Cancer Inst. 1973;51(4):1275-1285.
96. Ferguson DJ. Cellular attachment to implanted foreign bodies in relation to tumorigenesis. Cancer Res. 1977;37(12):4367-4371.
97. Moizhess TG. Carcinogenesis induced by foreign bodies. Biochemistry-Moscow. 2008;73(7):763-775.
98. Mally A, Chipman JK. Non-genotoxic carcinogens: early effects on gap junctions, cell proliferation and apoptosis in the rat. Toxicology. 2002;180(3):233-248.
99. Zhao C, Hayakawa Y, Kodama Y, et al. Denervation suppresses gastric tumorigenesis. Sci Transl Med. 2014;6(250):250ra115.
100. Romeo HE, Colombo LL, Esquifino AI, Rosenstein RE, Chuluyan HE, Cardinali DP. Slower growth of tumours in sympathetically denervated murine skin. J Auton Nerv Syst. 1991;32(2):159-164.
101. Kaminishi M, Shimizu N, Shimoyama S, et al. Denervation promotes the development of cancer-related lesions in the gastric remnant. J Clin Gastroenterol. 1997;25(Suppl 1):S129-S134.
102. Pawlowski A,Weddell G. Induction of tumours in denervated skin. Nature. 1967;213(5082):1234-1236.
103. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004;117(8):1495-1502.
104. Biskind MS, Biskind GS. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med. 1944;55(3):176-179.
105. Stevens LC. The development of teratomas from intratesticular grafts of tubal mouse eggs. J Embryol Exp Morpho. 1968;20(3):329-341.
106. Stevens LC. The development of transplantable teratocarcinomas from intratesticular grafts of pre-and postimplantation mouse embryos. Develop Biol. 1970;21(3):364-382.
107. Furth J, Sobel, H. Neoplastic transformation of granulosa cells in grafts of normal ovaries into spleens of gonadectomized mice. J Natl Cancer Inst. 1947;8(1):7-16.
108. Illmensee K, Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci U S A. 1976;73(2):549-553.
109. Webb CW, Gootwine E, Sachs L. Developmental potential of myeloid leukemia cells injected into rat midgestation embryos. Dev Biol. 1984;101(1):221-224.
110. Coleman W B, Wennerberg AE, Smith GJ, Grisham JW. Regulation of the differentiation of diploid and some aneuploid rat liver epithelial (stemlike) cells by the hepatic microenvironment. Am J Pathol. 1993;142(5):1373-1382.
111. McCullough KD, Coleman WB, Ricketts SL, Wilson JW, Smith GJ, Grisham JW. Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proc Natl Acad Sci U S A. 1998;95(26):15333-15338.
112. Gerschenson M, Graves K, Carson SD, Wells RS, Pierce GB. Regulation of melanoma by the embryonic skin. Proc Natl Acad Sci U S A. 1986;83(19):7307-7310.
113. Weaver V, Petersen O, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking bodies. J Cell Biol. 1997;137(1):231-245.
114. Bussard KM, Boulanger CA, Booth BW, Bruno RD, Smith GH. Reprogramming human cancer cells in the mouse mammary gland. Cancer Res. 2010;70(15):6336-6343.
115. D'Anselmi F, Masiello MG, Cucina A, et al. Microenvironment promotes tumor cell reprogramming in human breast cancer cell lines. PLoS ONE. 2013;8(12):e83770.
116. Haas D, Ablin AR, Miller C, et al. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer. 1988;62(4):818-825.
117. Bullock FD, Rohdenburg GL. A study of the Scharlach R reaction and of allied forms of epithelial proliferation. J Med Res. 1915;33(1):53-92.
118. Tatematsu M, Nagamine Y, Farber E. Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver. Cancer Res. 1983;43(11):5049-5058.
119. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G. Spontaneous " healing" of breast cancer. Breast Cancer. 2005;12(2):140-144.
120. Versteeg R. Cancer: tumours outside the mutation box. Nature. 2014;506(7489):438-439.
121. Collins FS. The future of medicine is about you. The Wall Street Journal. July 8, 2014:R9.
122. Baker SG. Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst. 2009;101(16):1116-1119.
123. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452-464.
124. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215.
125. Johnson KH, Ghobrial HK, Buoen LC, Brand I, Brand KG. Nonfibroblastic origin of foreign body sarcomas implicated by histological and electron microscopic studies. Cancer Res. 1973;33(12):3139-3154.
126. Barnes DWH, Evans EP, Loutit JF. Local origin of fibroblasts deduced from sarcomas induced in chimaeras by implants of pliable disks. Nature. 1971;233(5317):267-268.
127. Baker SG. Simple and flexible classification via Swirls-and-Ripples. BMC Bioinformatics. 2010;11:452.
128. Arentz G, Chataway T, Price TJ, et al. Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clin Proteomics. 2011;8(1):16.
129. Diss JK, Stewart D, Pani F, et al. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis. 2005;8(3):266-273.
130. Baker SG, Cappuccio A, and Potter JD. Research on earlystage carcinogenesis: Are we approaching paradigm instability? J Clin Oncol. 2010;28(20):3215-3218.
131. Heschel AJ, Heschel S, Neugroschel J. Maimonides: A Biography. 1981. Toronto, Canada: McGraw-Hill Ryerson.